AGC Biologics hit with 483 for poor discrepancy investigation practices, quality control issues at Washington site
FDA Issues Form 483 to AGC Biologics
CDMO AGC Biologics is constructing a new government-funded ¥50 billion ($350.5 million) facility at its Yokohama Technical Center in Japan, which is roughly half an hour’s drive from West Tokyo.
AGC Biologics Milan Receives Special Award Mention by Confindustria for Research and Innovation
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product
AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), entered into a new service agreement with Medigene AG. Under the agreement, AGC Biologics is providing autologous production for a next-generation-therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months
AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus
Cell and gene therapy manufacturing specialist AGC Biologics is continuing its rapid expansion and has added three new production suites to its site in Longmont, Colorado.